



*Better health through
laboratory medicine.*

PEARLS OF LABORATORY MEDICINE

Heparin-Induced Thrombocytopenia

Kristi J. Smock, MD

Associate Professor of Pathology
University of Utah Department of Pathology
Medical Director, Hemostasis/Thrombosis Laboratory
ARUP Laboratories



DOI: 10.15428/CCTC.2016.260455



Heparin-Induced Thrombocytopenia (HIT)

What is HIT?


- Immune mediated syndrome that occurs in a small percentage (1-5%) of heparin-exposed patients
- Caused by IgG antibodies to heparin-platelet factor 4 (PF4) complexes
- Immune complexes cause platelet activation
 - Thrombocytopenia
 - High risk of arterial or venous thrombosis
 - ~50% if untreated



Heparin-Induced Thrombocytopenia (HIT)

Pathogenesis

- PF4 released from platelet granules is positively charged
 - Able to form complexes with negatively charged heparin
- Heparin-PF4 complexes are antigenic in some patients, resulting in antibody formation
 - Immune complexes composed of IgG-heparin-PF4 activate platelets via the platelet Fcγ receptor for IgG



Heparin-Induced Thrombocytopenia (HIT)

Risk of HIT

- Higher risk in surgical patients than in medical patients
 - Related to amount of circulating PF4 and type and dose of heparin
 - Low risk in pregnancy
- Higher risk with unfractionated heparin (UFH) than low-molecular-weight heparin (LMWH)
 - Related to likelihood of complex formation, creation of HIT antigen



Heparin-Induced Thrombocytopenia (HIT)

HIT Diagnosis - Clinical

- Suspected when patient develops thrombocytopenia 5-10 days after heparin exposure
- Evaluation of clinical pre-test probability using clinical scoring system such as the 4T's system
 - Excellent negative predictive value (NPV) for low scores
 - NPV 97-99%
 - Poor positive predictive value (PPV) for intermediate or high scores
 - PPV for intermediate 10-20%
 - PPV for high 40-80%

Heparin-Induced Thrombocytopenia (HIT)

4T's scoring system

Thrombocytopenia

- 0 points; <30% drop or nadir <10 x 10⁹/L
- 1 point; 30-50% drop or nadir 10-19 X 10⁹/L
- 2 points; >50 drop and nadir >=20 X 10⁹/L

Timing of platelet drop

- 0 points; <4 days with no recent exposure
- 1 point; suspect 5-10 days but not documented, >10 days, <=1 day with last exposure 30-100 days prior
- 2 points; 5-10 days or <= 1 day if exposed in past 30 days

Thrombosis

- 0 points; none
- 1 point; progressive, recurrent, silent, suspected but not proven
- 2 points; proven new thrombosis or skin necrosis or acute systemic reaction to heparin

Other causes of thrombocytopenia

- 0 points; definite
- 1 point; possible
- 2 points; none

Scoring

Low = <4 points

Intermediate = 4-6 points

High = 6-8 points



Heparin-Induced Thrombocytopenia (HIT)

HIT Diagnosis - Laboratory

- 2 categories of tests
 - Immunoassays to detect heparin-PF4 antibodies
 - ELISA is most common
 - Functional assays to detect platelet activation by HIT immune complexes

Heparin-Induced Thrombocytopenia (HIT)

HIT Diagnosis - ELISA

- Plates coated with heparin-PF4
- Detect antibodies in patient serum
 - IgG/IgM/IgA – polyspecific
 - IgG only – monospecific
- Diagnostic utility
 - Excellent NPV (~99%)
 - High sensitivity (95-100%)
 - Poor specificity (<90%, possibly well below 90%) and poor PPV since many patients who develop antibodies do not develop the HIT syndrome
 - Specificity somewhat improved with monospecific IgG ELISA

Heparin-Induced Thrombocytopenia (HIT)

HIT Diagnosis - ELISA

- Specificity improved by considering the optical density (OD) value of positive results
- Higher OD values correlate with capacity for platelet activation
 - 0.4 to 1.0: ~5% probability of HIT
 - 1.0 to 1.5: ~25% probability of HIT
 - ≥ 2.0 : ~90% probability of HIT
- Unclear if repeating positive samples in the presence of a high heparin concentration significantly improves ELISA specificity
 - Possible risk of false-negative results



Heparin-Induced Thrombocytopenia (HIT)

HIT Diagnosis – Functional platelet activation assays

- Sensitive (>90%) and more specific (>90%) for HIT than ELISA due to demonstration of antibody platelet activating properties
- Serotonin release assay (SRA) is the most commonly used test and golden standard
 - Further evaluate unexpected ELISA results
 - Further evaluate positive ELISA results



Heparin-Induced Thrombocytopenia (HIT)

HIT Diagnosis – SRA

- Combine patient serum with donor platelets and heparin
 - HIT positive sera result in platelet activation and release of serotonin from dense granules
 - Released serotonin is detected and quantified as an indicator of the degree of platelet activation
 - A variety of methods can be used to quantify serotonin



Heparin-Induced Thrombocytopenia (HIT)

HIT Diagnosis – SRA results

- Released serotonin expressed as % release
 - Amount of serotonin released divided by total platelet serotonin X 100
 - $\geq 20\%$ release represents platelet activation
- Each patient specimen is tested at 2 different heparin concentrations and % release values are obtained
 - Low heparin concentration (LH) – therapeutic, supports immune complex formation
 - High heparin concentration (HH) – supra-therapeutic, disrupts immune complex formation



Heparin-Induced Thrombocytopenia (HIT)


SRA reaction patterns

LH % Release	HH % Release	Classification
$\geq 20\%$	$< 20\%$	Positive
$< 20\%$	$< 20\%$	Negative
$\geq 20\%$	$\geq 20\%$	Indeterminate



Heparin-Induced Thrombocytopenia (HIT)

Diagnostic algorithm for suspected HIT



References

1. Greinacher A. Heparin-induced thrombocytopenia. *NEJM* 2015;373:252-61.
2. Warkentin TE. HITlights: A career perspective on heparin-induced thrombocytopenia. *Am J Hematol* 2012;87:S92-9.
3. Warkentin TE. How I diagnose and manage HIT. *Hematology Am Soc Hematology Educ Program* 2011;2011:143-9.
4. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. *J Thromb Haemost* 2006;4:759-65.
5. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. *Blood* 2012;120:4160-7.
6. Warkentin TE, Sheppard JI, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need? *J Lab Clin Med* 2005;146:341-6.
7. Warkentin TE, Sheppard JI, Moore JC, et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. *J Thromb Haemost* 2008;6:1304-12.
8. Greinacher A, Ittermann T, Bagemuhl, et al. Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. *J Thromb Haemost* 2010;8:2025-31.
9. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. *Blood* 1986;67:27-30.
10. Sono-Koree NK, Crist RA, Frank EL, et al. A high-performance liquid chromatography method for the serotonin release assay is equivalent to the radioactive method. *Int J Lab Hematol* 2016;38:72-80.

Disclosures/Potential Conflicts of Interest

Upon Pearl submission, the presenter completed the Clinical Chemistry disclosure form. Disclosures and/or potential conflicts of interest:

- **Employment by the University of Utah Department of Pathology and ARUP Laboratories**



Thank you for participating in this
Clinical Chemistry Trainee Council
Pearl of Laboratory Medicine.

Find our upcoming Pearls and other
Trainee Council information at
www.traineecouncil.org

Download the free *Clinical Chemistry* app
on iTunes today for additional content!

Follow us:

